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Liaison Psychiatry, Brandon Mental Health Unit, Leicester General Hospital, Leicester, UK
Objective: To descr ibe a ho listic and comprehensive approach to the assessment of sufferer ’s perceptio ns o f health-r elated quality of life
(HRQ oL) in a cohor t of multiple sclero sis (MS) patients. Methods: The GEDMA (G rupo de Enfermedades Desmielinizantes de Madrid, in
Spanish) study is an ongo ing longitudinal survey using quantitative and qualitative methodologies. The baseline cohort consisted of a large
sample o f MS patients recruited from 13 hospitals in Madr id, Spain. Using a standardized protocol we collected data concerning the
sociodemographic and health status character istics o f patients, as well as implementing a modified Spanish version of the Functio nal
A ssessment of Multiple Sclerosis quality of life instrument. Pr imary caregivers were interviewed using a specific pro toco l combined with
the Zarit Burden Inter view. Results: The index cohort comprised 371 MS patients (68.7% female) o f mean age 38.99/0.9 years. A ge, sex
and clinical form distr ibution were similar to o ther MS population-based surveys. There were 258 (69.5%) relapsing¡/remitting (RR) MS
patients and 113 (30.5%) progressive MS patients. More than one-thir d of the married patients with progressive MS and almost a quarter
o f the RRMS patients separated or divorced fo llowing a diagnosis of MS; 71.3% of the progressive MS patients as well as 65.8% of the
RRMS patients were unemployed as a consequence of the disease. Q ualitative analysis showed that friendship and family relatio nships and
occupational status were the most significant dimensions influenced by MS. O n the other hand, the speech analysis o f pr imary caregivers
showed that emotional burden was related to patients’ physical disability. Furthermore, pr imary caregivers descr ibed the influence of MS
on their own occupatio nal status, their nonacceptance of the disease, a perceptio n of a lack of suppo rt by other members o f the family as
well as a ‘selfish and intransigent’ attitude of the patients themselves. Conclusions: The analysis o f the GEDMA cohort provides valuable
information that helps clar ify the impact o f MS on patients’ HRQ oL.
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Key words: health-related quality of life; multiple sclerosis; prospective study; qualitative methodology; quantitative survey
Introductio n
Multiple sclerosis (MS) is one of the most common causes
of chronic disability in young adults. The core symptoms
of MS considerably impact upon the activities of daily
living of patients. In addition, the disease has important
psychological and, not infrequently, psychiatric conse-
quences.1 This combination means that MS affects the
quality of life (QoL) experienced by patients and their
families to a greater extent than several other chronic
diseases.2,3
QoL is a term used in social science to refer to a
subjective sense of wellbeing or global satisfaction with
important aspects of life. In public health and medicine,
the concept of health-related quality of life (HRQoL) refers
to those aspects of life quality or function that are
influenced by health status. This term is more specific
than QoL and is based on health dimensions that can be
measured. Tracking HRQoL in different populations can
identify subgroups associated with particular physical or
mental health complications, which may help guide
policies or interventions to improve their health. As a
result, assessment of HRQoL is increasingly becoming
important for clinical research, clinical practice and
service planning in health policy.4¡ 8
The aim of this article is to describe a comprehensive
methodological approach to the assessment of patients’
perception of HRQoL: the GEDMA (Grupo de Enferme-
dades Desmielinizantes de Madrid, in Spanish) study.
Methods
General study design
The GEDMA group was constituted in 1998 by a cohort of
Spanish neurologists with expertise in MS. In 1999, a
specific study regarding the HRQoL in a sample of MS
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patients and their primary caregivers was proposed: the
GEDMA study. The baseline cohort consisted of a sample
of MS patients from 13 Spanish hospitals in Madrid. MS
patients were recruited by random sampling from MS
databases in each hospital (see below for eligibility criteria
of this study).9¡ 13 The GEDMA study began in 2000 and
the MS cohort was followed over two years. Evaluations
included changes in physical, psychological and social
domains. The study was approved by the Móstoles
General Hospital Research Ethics Board.
Eligibility criteria The eligibility criteria were those used
in a previous HRQoL survey of MS.14 Patients, aged 18
and over, were included in the study if they had met the
Poser committee diagnostic criteria for at least three
months before inclusion and gave informed consent.15
Patients excluded from the study were those a) institutio-
nalized at the time of observation, b) those who had major
acute comorbidities or any major serious chronic illness
three months before inclusion (patients with a stable
chronic medical condition were included), c) patients
with any neurological illness other than MS, and d) those
who had participated in any drug- or nondrug-related
trials in the past three months.
Caregivers were selected for the study if they dedicated
to the care of patients at least one hour a day.16
Quantitative methodology Each patient gave his/her in-
formed consent after the nature of the study and its
procedure was fully explained by mail. The interviewer
made an appointment by telephone to administer the
protocol in the hospital setting or at home, depending on
the patient’s preference. Patients included in the baseline
cohort were interviewed with a standardized question-
naire. The instruments were all administered face-to-face
by a sociologist (JR-N) specialized in health sciences.
When the patient was not capable of filling in the
questionnaires because of physical problems, assistance
was provided. This protocol was structured to include the
following aspects (the main questionnaires are described
below): a) social and demographic data; b) HRQoL
measured with a modified Spanish version of the Func-
tional Assessment of Multiple Sclerosis (FAMS) QoL
instrument;17,18 c) care needs or technical helps in the
daily life as well as the existence of architectonic barriers
at home and in the neighbourhood; d) the influence of the
disease on educational or working activities; e) an exam-
ination of how distressing situations affect the disease
process; f) attitudes of the family members towards the
disease and how it affects the partner relationship; g) the
use of alternative therapies; and h) emotional and cogni-
tive functioning.
Caregivers were interviewed using a questionnaire
covering social and demographic data, relationship with
the patient, daily hours of care, care at night, influence of
MS on the caregiver’s occupational life, drugs for caregiver
depression, and support received from other members of
the family and/or formal caregivers. Lastly, caregiver
burden measured with a Spanish adaptation of the Zarit
Burden Interview (see later) was administered.19,20
Qualitative methodo logy The qualitative methodology
consisted of three focus groups composed of patients
and another one composed of primary caregivers to
discuss the needs and attitudes towards the disease. The
focus groups were conducted at the same time as the
structured interviews. Regarding the patient assessments,
the main aspects that were analysed were the influences of
the disease on the family (including marital aspects) and
social networks (relatives, friends, and neighbors), the
relationship between disease and working life, and their
handicaps resulting from physical disabilities. Regarding
family caregivers, we wanted to study in depth the
understanding they had about the consequences of this
disease upon other relatives as well as the conflicts the
disease had caused within the different dimensions of life.
Clinical variables The main clinical characteristics were
obtained from review of well-documented neurological
records. An Expanded Disability Status Scale (EDSS) score
was assigned by each clinical neurologist.21 Four clinical
variables were used to form subgroups of MS patients:
gender; EDSS score; disease duration; and clinical course.
Three subgroups were formed according to EDSS score: a)
low physical disability (EDSS 0¡/2.5); moderate physical
disability (EDSS 3.0¡/5.5); and high physical disability
(EDSS ]/6.0). Disease duration was defined as the period
between the first symptom and the assessment day. For
clinical course, two subgroups were defined: relapsing¡/
remitting (RR) and progressive [secondary progressive
(SP) or primary progressive (PP)].
Main questionnaires of the study protocol
HRQ oL instrument In its original version, the FAMS QoL
instrument is an MS-specific HRQoL assessment that
captures six main HRQoL domains: a) Mobility (seven
items); b) Symptoms (seven items); c) Emotional Well-
being (seven items); d) General Contentment (seven
items); e) Thinking/Fatigue (nine items); and f) Family/
Social Wellbeing (seven items).17 An analysis of this
modified FAMS version, applied in a sample of Spanish
MS patients, showed slightly higher reliability if eight
additional MS-specific items, which had been initially
excluded from the original version, were now included.18
In this survey, we applied both the original Spanish
translated version of the FAMS QoL instrument as well
as the modified version.
Cognitive functioning instruments Study participants were
administered a version of the Mini-Mental State Examina-
tion (MMSE). A few simple cultural modifications were
necessary. ‘State’ was replaced by ‘Country’, and instead
of being asked for the ‘County’, subjects were asked for the
names of two main streets nearby. Apart from this, the test
was carried out as described in the original version, 30
points being the highest possible result.22 Furthermore,
the clock drawing test (CDT) was also implemented. Clock
drawings were administered with the command version;
10 points being the best possible result.23
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Emotional functioning instruments Depression symptoms
were assessed with a Spanish version of the Hamilton
Rating Scale for Depression (17-item version);24 scores
range from 0 to 52 points. Anxiety symptoms were
assessed with a Spanish version of the Hamilton Rating
Scale for Anxiety (14-item version);25 scores range from 0
to 56 points. In both instruments, higher scores indicate
higher levels of depression and anxiety, respectively.
Caregiver burden instrument Caregiver burden was as-
sessed with the Zarit Burden Interview. This generic scale
consists of 22 items that examine the impact of the care
receiver’s disabilities on the caregiver’s emotional, social,
physical and financial wellbeing.19,20 The Burden Inter-
view is scored by summing the responses to the individual
items. The possible range is from 0 to 88. A higher score
indicates a greater level of burden.
Results
Main characteristics of the GEDMA cohort
Of the 484 MS patients who were deemed eligible for the
study, 371 persons (76.6%) were interviewed. The remain-
ing 113 subjects were lost to the study because of address
change (83, 73.4%), refusal (29, 25.6%) or death (one,
0.9%). There were no statistically significant differences
in age groups (x2¾/5.407, P¾/0.14), sex (x2¾/2.138, P¾/
0.14) and clinical course of MS (x2¾/4.525, P¾/0.10)
between those subjects who participated in the study
and those who did not participate. The index study cohort
then composed of 371 MS patients (68.7% female), mean
age 38.99/0.9 years (range 18¡/74 years). Table 1 shows the
age and sex distribution of this cohort. The age distribu-
tion was similar to other population-based cross-sectional
surveys (Table 2). Table 3 shows the age and sex distribu-
tion of the GEDMA cohort according to the clinical course.
This comprised 69.5% RRMS and 30.5% progressive MS
of which 80 patients (21.6%) had SPMS. Figure 1 shows
that the clinical distribution in the GEDMA cohort was not
significantly different from other population-based cross-
sectional surveys. Detailed clinical information defined by
clinical course is shown in Table 4. Of the RRMS patients,
78.3% were fully ambulatory, while 89.4% of the pro-
gressive MS patients required aid for ambulation, with
more than 75% using canes, crutches or wheelchairs.
Table 5 shows the mean scores on the FAMS QoL
instrument version of the RRMS and the progressive MS
patients. With regard to the psychosocial factors, Table 6
shows that more than one-third of the married patients
with progressive MS and almost one-quarter of the RRMS
patients separated or divorced because of the disease.
Moreover, 71.3% of the progressive MS patients, as well as
65.8% of the RRMS patients, were unemployed as a
consequence of the disease.
The main characteristics of the MS patients’ caregivers
of the GEDMA cohort have been recently published.16
Focus groups results
The main characteristics of the subjects that composed
these groups are shown in Table 7. Open-ended questions
were asked about areas of main concern to MS patients.
Four sessions were carried out to allow discourses of both
the patients and the primary caregivers. These were
focused on different dimensions of family and occupa-
tional life.
The speech analysis of patients showed that friendship
and family relationships as well as occupational domains
were the most important dimensions influenced by MS.
All patients who participated in the focus groups revealed
that unemployment was a difficult issue. Strategies to
minimize this problem included improving the economic
conditions of the invalidity/incapacity benefit or facing
the lack of job opportunities through participation in
patients’ organizations. On the other hand, the speech
analysis of primary caregivers showed that emotional
burden was related to patients’ physical disability.
Furthermore, primary caregivers described the influence
of MS on their own occupational status, their nonaccep-
tance of the disease, a perception of a lack of support by
other members of the family, as well as a ‘selfish and
intransigent’ attitude of the patients themselves.
Discussion
MS has major consequences on HRQoL among MS
patients and their relatives.26,27 However, contrary to
physicians’ beliefs, physical disability is not always the
main determinant of overall HRQoL. Indeed, physicians
Table 1 Age and sex distribution of the GEDMA cohort
Age Women Men Both sexes
No. of cases % No. of cases % No. of cases %
5/24 17 6.7 9 7.8 26 7.0
25¡/29 37 14.5 13 11.2 50 13.5
30¡/34 52 20.4 18 15.5 70 18.9
35¡/39 46 18.0 16 13.8 62 16.7
40¡/44 39 15.3 19 16.4 58 15.6
45¡/49 30 11.8 13 11.2 43 11.6
50¡/54 16 6.3 13 11.2 29 7.8
]/55 18 7.1 15 12.9 33 8.9
Total 255 100.0 116 100.0 371 100.0
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are more concerned than MS patients about the physical
manifestations of disease. Patients themselves, identify
vitality, role limitations caused by emotional problems,
bodily pain and mental health as the most important
determinants of their overall QoL.28,29 Interestingly, MS
may affect patient’s HRQoL dramatically even in those
with low EDSS scores and when impairment of mobility is
not yet a major complaint.30 That said, there is a relation-
ship between HRQoL and clinical course. A recently
published investigation demonstrated that a long duration
of illness and high illness severity correlated with low
HRQoL.31 These findings are not necessarily contradic-
tory, as certain complications of MS impact upon indivi-
duals early in the disease course, while others impact late.
An analysis of the GEDMA cohort supported these find-
ings.32
Emotional (depression and anxiety), cognitive and
social status play an important role in patient’s
HRQoL.30,32¡ 36 Our assessments of cognitive, depressive
and anxiety complications were graded by rating scales.
Specifically, we decided to use the CDT and MMSE
because both instruments have been recommended as a
brief cognitive testing in MS.37 Our aim was not to make a
definitive clinical diagnosis of cognitive dysfunction or
mood disorder but to assess the influence of neuropsy-
chiatric symptoms on HRQoL. In our previous analysis of
the GEDMA cohort, we showed that poor cognitive
function and the high depressive and anxiety symptoms
were associated with the low HRQoL scores.32 In our view
clinicians should supplement HRQoL measurement in MS
patients with assessment of cognitive and emotional
aspects. These frequently overlooked symptoms dramati-
cally impact upon patient and caregiver wellbeing more
than any other single dimension.38Once recognized, such
Table 2 Age distribution of the GEDMA cohort compared with three Spanish prevalence studies of MS
GEDMA, n¾/371 Alcoya , n¾/54 Teruelb , n¾/46 Móstolesc , n¾/85
n % n % n % n %
5/29 76 20.5 17 20.0 10 21.7 8 14.8
30¡/44 190 51.2 45 52.9 19 41.2 24 44.4
45¡/54 72 19.4 16 18.8 10 21.7 15 27.8
]/55 33 8.9 7 8.2 7 15.2 7 13.0
a See reference number [7].
b See reference number [10].
c See reference number [11].
Table 3 Clinical form distribution of the GEDMA cohort by sex and age
Age groups by sex Clinical forms Total
RRMS Progressive forms
No. of cases % No. of cases % No. of cases %
5/24 Women 15 57.7 2 7.7 17 65.4
Men 8 30.8 1 3.8 9 34.6
25¡/34 Women 75 62.5 14 11.7 89 74.2
Men 25 20.8 6 5.0 31 25.8
35¡/44 Women 62 51.7 23 19.2 85 70.8
Men 25 20.8 10 8.3 35 29.2
45¡/54 Women 27 37.5 19 26.4 46 63.9
Men 10 13.9 16 22.2 26 36.1
]/55 Women 7 21.2 11 33.3 18 54.5
Men 4 12.1 11 33.3 15 45.5
Total Women 186 50.1 69 18.6 255 68.7
Men 72 19.4 44 11.9 116 31.3
Figure 1 Clinical forms distribution of the GEDMA cohort
compared with three Spanish prevalence studies of MS.
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complications are treatable and this treatment has been
shown to improve HRQoL.39
Despite great strides in this field, further longitudinal
studies are essential in order to clarify the following
questions. First, what is the relationship between indivi-
dual complications of MS and HRQoL at each stage of the
disease and in each disease subtype? Secondly, what are
the modifying factors mediating disability and HRQoL (in
particular the role of coping styles, social support and
doctor¡/patient variables)? Thirdly, what is the effect of
new drug treatments for MS on HRQoL, and how is this
influence explained (for example, through functional,
cognition, social or emotional benefits)?40¡ 43 All of these
questions encouraged us to develop the GEDMA project.
Table 4 Clinical characteritics of the RR and the progressive MS patients
RR Progressive forms Total
n¾/258 % n¾/113 % n¾/371 %
EDSS score 2.449/1.6 6.319/1.3 3.629/2.3
5/2.5 152 58.9 1 0.9 153 41.2
3¡/5.5 97 37.6 29 25.7 126 34.0
]/6.0 9 13.5 83 73.5 92 24.8
Disease duration (years) 9.49/6.3 12.99/8.1 10.29/7.1
Aid for ambulation
Fully ambulatory 202 78.3 12 10.6 214 57.7
Walking with aid of another person 25 9.7 12 10.6 37 10.0
Walking with aid of cane or crutches 26 10.1 41 36.3 67 18.1
Wheelchair bound 5 1.9 45 39.8 50 13.5
Bed bound 0 0 3 2.7 3 0.8
Mean age at onset (years) 27.29/8.9 32.09/11.5 28.79/10.0
Table 5 Score on the FAMS quality of life instrument version of








Emotional wellbeing 21.79/6.0 15.99/7.6
General contentment 24.09/6.6 16.59/8.3
Thinking/fatigue 23.49/8.8 19.29/8.8
Family/social wellbeing 22.39/4.7 20.69/5.4
Total FAMS 149.69/35 114.69/32.3
Higher scores reflect better quality of life.
Table 6 Psychosocial characteristics of the GEDMA cohort according to clinical course









Married 143 55.4 19 69.9 222 59.8
MS affects couple relationship 45 17.4 40 35.4 85 22.9
Separated/divorced because of MS 11 24.4 15 37.5 26 30.6
Labour status
Active/full-time employment 112 43.4 12 10.6 124 33.4
MS has negative repercussions on employment 71 63.4 12 100.0 41 33.1
Unemployed because of MS 96 65.8 72 71.3 168 68.0
Neighbourhood status
Patients who refer the presence of architectonical barriers 101 39.1 79 69.9 180 48.5
Patients with troubles to get around in public placesa 36 13.9 74 65.5 110 29.6
Family and social supporta
Patients who get emotional support from family 230 89.2 91 80.5 321 86.5
Patients whose family has accepted MS 215 83.3 84 73.3 299 80.6
Patients whose family has trouble understanding when MS gets worse 144 55.8 82 72.6 226 60.9
Patients who feel distant from friends 203 78.7 65 57.5 268 72.3
Patients who get support from friends and neighbours 200 77.5 66 58.4 266 71.7
Patients who feel ‘left out’ of things 18 7.0 15 13.3 33 8.9
Patients who have to limit social activity because of MS 59 22.9 77 68.1 136 33.6
a These items have been extracted from the FAMS QoL instrument.
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The main goal of our study was to obtain and define an MS
cohort representing the entire clinical spectrum of the
disease. To our knowledge, only six previous cross-
sectional studies have obtained a representative sample
of MS patients.26,44¡ 48 Unlike these studies, ours used a
face-to-face interview, which facilitated an atmosphere of
confidence for patients to discuss their problems and
difficulties. An interviewer may also tailor an interview to
suit a subject’s particular life circumstances by explaining
unclear terms or ideas. This is a particularly important
consideration when working with a disease with a high
prevalence of cognitive impairment, such as MS.
Any approach centred around the patient’s perception
of HRQoL may be enhanced by combining quantitative
and qualitative methodologies. To date, only one pub-
lished study has used both methodological approaches in
MS.34 However, unlike the current survey, they did not
compare qualitative data with quantitative results. The
analysis of our cohort will allow us to obtain qualitative
information about the needs of MS patients and illness
intrusiveness according to the statements of themselves
and their primary caregivers. The qualitative design has
been useful for the screening of social values that
determine attitudes and behaviours towards the disease.
This technique permits us to obtain information about the
perception and affection of the disease in both the patients
and their caregivers. Furthermore, our ongoing longitudi-
nal study will allow us to obtain information about the
issues of MS patients’ caregivers. A preliminary analysis
in 91 primary MS patients’ caregivers of the GEDMA
cohort showed that patients’ HRQoL is strongly related to
the burden of their caregivers.16
We used both the Spanish translation of the original
FAMS QoL instrument as well as a modified version to
assess the HRQoL in our sample of MS patients.17,18 The
original version of the FAMS is a very useful, disease-
targeted, instrument to evaluate MS patients’ HRQoL.17,46
However, although the original version of the FAMS
instrument includes the dimension of interest, its main
limitation is that it is overly weighted toward assessment
of psychosocial consequences.45 In contrast, the Spanish
modified version of the FAMS instrument has seven
additional items concerning MS symptoms. In work to
date it is a valid instrument that allows researchers to
accurately measure the HRQoL concerns of MS patients.18
We feel that the modified FAMS offers a more holistic
assessment of neurological symptoms and psychosocial
complaints associated with MS in line with published
recommendations regarding specific HRQoL instru-
ments.49,50 We hope that analysis of the GEDMA cohort
will help to improve our understanding of the way in
which various facets of MS impact upon patients’ HRQoL.
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HacẂa la búsqueda de dimensiones más especicas en la
medición de la calidad de vida en la esclerosis múltiple. Rev
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